BR112017011538A2 - combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) - Google Patents
combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)Info
- Publication number
- BR112017011538A2 BR112017011538A2 BR112017011538A BR112017011538A BR112017011538A2 BR 112017011538 A2 BR112017011538 A2 BR 112017011538A2 BR 112017011538 A BR112017011538 A BR 112017011538A BR 112017011538 A BR112017011538 A BR 112017011538A BR 112017011538 A2 BR112017011538 A2 BR 112017011538A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- combination
- myeloma
- treat cancer
- enhancing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462087489P | 2014-12-04 | 2014-12-04 | |
PCT/US2015/063585 WO2016090070A1 (en) | 2014-12-04 | 2015-12-03 | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017011538A2 true BR112017011538A2 (pt) | 2018-03-13 |
Family
ID=55022696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017011538A BR112017011538A2 (pt) | 2014-12-04 | 2015-12-03 | combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) |
Country Status (13)
Country | Link |
---|---|
US (1) | US20170355768A1 (pt) |
EP (1) | EP3227335A1 (pt) |
JP (1) | JP2017537927A (pt) |
KR (1) | KR20170088984A (pt) |
CN (1) | CN107249632A (pt) |
AU (1) | AU2015358462A1 (pt) |
BR (1) | BR112017011538A2 (pt) |
CA (1) | CA2969665A1 (pt) |
EA (1) | EA201791049A1 (pt) |
IL (1) | IL252535A0 (pt) |
MX (1) | MX2017007097A (pt) |
SG (1) | SG11201704343SA (pt) |
WO (1) | WO2016090070A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112125884A (zh) | 2010-12-17 | 2020-12-25 | 诺华股份有限公司 | 制备嘧啶-2,4-二胺二盐酸盐的方法 |
SG194701A1 (en) | 2011-04-29 | 2013-12-30 | Apexigen Inc | Anti-cd40 antibodies and methods of use |
US10344090B2 (en) | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
AU2017353852A1 (en) * | 2016-11-02 | 2019-05-23 | Apexigen, Inc. | Anti-CD40 antibodies in combination and methods of use |
US20210155691A1 (en) * | 2018-04-16 | 2021-05-27 | Adaerata, Limited Partnership | Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
JP3793693B2 (ja) | 1998-12-23 | 2006-07-05 | ファイザー インコーポレーテッド | Ctla−4に対するヒトモノクローナル抗体 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
BR0008379A (pt) | 1999-02-22 | 2002-09-24 | Biotechnolog Forschung Gmbh | Epotilonas modificadas em c-21 |
HU228477B1 (en) | 1999-08-23 | 2013-03-28 | Dana Farber Cancer Inst Inc | Pd-1, a receptor for b7-4, and uses therefor |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
NZ581541A (en) | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
US6958115B2 (en) | 2003-06-24 | 2005-10-25 | The United States Of America As Represented By The Secretary Of The Navy | Low temperature refining and formation of refractory metals |
CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド1(pd−l1)に対するヒトモノクローナル抗体 |
US7842293B2 (en) | 2006-08-07 | 2010-11-30 | Facet Biotech Corporation | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
CN101686971B (zh) | 2006-08-07 | 2013-09-11 | 艾伯特生物治疗学公司 | 用于治疗多发性骨髓瘤的药物产品及其用途 |
US20080095768A1 (en) | 2006-08-07 | 2008-04-24 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
KR20110096536A (ko) | 2008-10-31 | 2011-08-30 | 애보트 바이오테라퓨틱스 코포레이션 | 희귀 림프종의 치료를 위한 항cs1 항체의 용도 |
US20130058921A1 (en) | 2009-10-30 | 2013-03-07 | Frits VAN RHEE | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
US20130052158A1 (en) | 2009-10-30 | 2013-02-28 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
-
2015
- 2015-12-03 JP JP2017529805A patent/JP2017537927A/ja not_active Withdrawn
- 2015-12-03 BR BR112017011538A patent/BR112017011538A2/pt not_active IP Right Cessation
- 2015-12-03 CN CN201580065674.2A patent/CN107249632A/zh active Pending
- 2015-12-03 US US15/531,538 patent/US20170355768A1/en not_active Abandoned
- 2015-12-03 KR KR1020177017909A patent/KR20170088984A/ko unknown
- 2015-12-03 CA CA2969665A patent/CA2969665A1/en not_active Abandoned
- 2015-12-03 MX MX2017007097A patent/MX2017007097A/es unknown
- 2015-12-03 EA EA201791049A patent/EA201791049A1/ru unknown
- 2015-12-03 WO PCT/US2015/063585 patent/WO2016090070A1/en active Application Filing
- 2015-12-03 EP EP15816310.5A patent/EP3227335A1/en not_active Withdrawn
- 2015-12-03 SG SG11201704343SA patent/SG11201704343SA/en unknown
- 2015-12-03 AU AU2015358462A patent/AU2015358462A1/en not_active Abandoned
-
2017
- 2017-05-25 IL IL252535A patent/IL252535A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3227335A1 (en) | 2017-10-11 |
MX2017007097A (es) | 2017-09-05 |
IL252535A0 (en) | 2017-07-31 |
SG11201704343SA (en) | 2017-06-29 |
EA201791049A1 (ru) | 2017-10-31 |
CN107249632A (zh) | 2017-10-13 |
KR20170088984A (ko) | 2017-08-02 |
CA2969665A1 (en) | 2016-06-09 |
US20170355768A1 (en) | 2017-12-14 |
WO2016090070A1 (en) | 2016-06-09 |
AU2015358462A1 (en) | 2017-07-27 |
JP2017537927A (ja) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123957T1 (el) | Θεραπεια συνδυασμου για καρκινο | |
CO2018003500A2 (es) | Anticuerpos anti-pd-1 y composiciones | |
BR112017011538A2 (pt) | combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) | |
DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
BR112017000664A2 (pt) | anticorpo anti-pd-1 e seu uso | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
GT201700102A (es) | Conjugados de anticuerpo-fármaco | |
CO2017008804A2 (es) | Receptores de antígeno quiméricos anti–dll3 y métodos de uso | |
PH12016501411B1 (en) | Bifunctional cytotoxic agents | |
EA201992757A1 (ru) | Биспецифические антитела-ингибиторы контрольной точки | |
BR112017010324A2 (pt) | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula | |
BR112017001588A2 (pt) | conjugados de anticorpo/fármaco anti-cdh6 | |
BR112016003394A2 (pt) | usos de um antagonista de pd-1 e um agonista do gitr e de um anticorpo biespecífico ou fragmento de ligação do antígeno do mesmo, e, combinação farmacêutica | |
MX2017004526A (es) | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. | |
BR112017006940A2 (pt) | triazolopirazinonas como inibidores de pde1 | |
MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
MA40612A (fr) | Nouveaux anticorps anti-mfi2 et méthodes d'utilisation | |
CL2016001753A1 (es) | Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
BR112017002433A2 (pt) | anticorpos anticeramida | |
WO2018009507A8 (en) | COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE | |
BR112019006504A2 (pt) | regime de dosagem de avelumabe para o tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |